Jump to section

Kaynes Technology India (KAYNES.NS) — Investment Thesis

Status: OWNED (31 shares, ₹1.22L invested, 12% of portfolio)

Quality Score: 17/25 (Grade B: Moderate Conviction)

Last Updated: 2026-03-19

Data Source: Screener.in (consolidated) + yfinance

Quick Summary

One-line thesis: India's leading high-reliability EMS company with PLI, defence, and OSAT tailwinds — capex cycle peaked and OPM recovery underway, but at ₹3,726 (63x P/E) the stock remains expensive even with anchored growth assumptions; DCF base ₹1,669 and bull ₹2,426 both trail CMP significantly, confirming genuine overvaluation not a modelling failure.

Action: HOLD — do not add until promoter selling resolves or P/E compresses below 35x forward

Level	Price	Trigger
Buy / Add	₹2,000 – ₹2,400	Between DCF base (₹1,669) and bull (₹2,426) — at ₹2,200, risk/reward is attractive if OPM recovery to 15-16% is confirmed; also requires promoter selling to stop
Hold	₹2,400 – ₹4,500	Current range (CMP ₹3,726) — capex cycle peaked, OPM recovery in motion; hold existing position
Sell / Exit	Above ₹5,500 or at trigger	Revenue growth drops below 20% YoY; OPM stays below 12% for 3 quarters (structural, not transitional); promoter drops below 48%

Why now (Mar 2026): Stock is 52% off peak (₹7,705). The capex-driven FCF trough is behind us (CapEx fell from ₹1,505 Cr to ₹355 Cr). Promoter selling concern partially resolved — the 10.1% total drop (Mar 2023→Dec 2025) happened in two discrete block sales, not continuous selling, and has stopped for 2 quarters. Still needs management explanation at Q4 FY26 concall.

1. Business Summary

India's leading end-to-end IoT solutions and electronics manufacturing services (EMS) company. Serves automotive, industrial, aerospace & defence, railways, and medical electronics. Founded 1988 in Mysore, listed 2022. The thesis is India's electronics manufacturing push (PLI scheme) + import substitution creating a massive TAM for domestic EMS players.

2. Quality Score

Dimension	Score (1-5)	Notes
MOAT	3	EMS is competitive globally, but Kaynes has niche in high-reliability segments (defence, aerospace, medical). PCBA + box-build + design = higher value chain. Not a pure contract manufacturer.
Management	4	Promoter-led (Ramesh Kunhikannan), 53.46% promoter holding — strong skin in the game. Aggressive capacity expansion. Track record of 49% 5Y sales CAGR.
Financials	3	ROE 11%, ROCE 14.3% — decent but not exceptional. OPM 15% typical for EMS. Debt ₹903Cr is meaningful (D/E ~0.5). Growing fast but margins under pressure from expansion capex.
Growth Runway	5	India EMS market growing 30%+ CAGR. Defence localization mandate. PLI scheme benefits. Revenue 5Y CAGR 49%. Order book visibility strong. Expanding into OSAT (semiconductor packaging).
Valuation	2	P/E 64.6 is very expensive. P/B 5.7x for 11% ROE — hard to justify. Market pricing in massive growth. DCF says overvalued even in bull case.
Total	17/25	Grade B: Moderate Conviction

3. Why This Could Be a Multi-Bagger

Catalyst 1: India electronics manufacturing boom. Govt targeting $500B electronics production by 2030 (from ~$100B). Kaynes positioned as quality domestic supplier.
Catalyst 2: Defence/aerospace localization. Govt mandating indigenous content in defence procurement. Kaynes has DRDO/HAL relationships and defence certifications.
Catalyst 3: OSAT entry. Kaynes entering semiconductor packaging (OSAT) — if successful, this is a massive margin and TAM expansion from EMS into semicon.
Catalyst 4: Operating leverage. New facilities coming online (Chamarajanagar, Telangana). As utilization ramps, OPM could expand from 15% to 18-20%.

4. Key Metrics (Consolidated)

Metric	FY23	FY24	FY25	TTM
Revenue (Cr)	1,156	1,822	2,722	~3,000*
Net Profit (Cr)	85	185	293	~320*
OPM %	14%	14%	15%	~15%
ROCE %	—	—	14.3%	—
ROE %	—	—	11%	—
Debt/Equity	—	—	~0.5	—
Promoter %	—	—	53.46%	53.46%
P/E	—	—	—	64.6
P/B	—	—	—	5.7

*TTM estimated from trailing quarters.

5Y Growth

Sales CAGR: 49%
Profit CAGR: 95%

5. Valuation

Current Price: ₹3,726 (updated Mar 2026 — near 52-week low)
52-week range: ₹3,295 – ₹7,705 (down 52% from peak)
Market Cap: ₹24,967 Cr
P/E (TTM): 63x | P/E (Forward): 42x
P/B: 5.2x | Book Value: ₹715/share
Shares Outstanding: ~6.7 Cr

Critical Signal: Revenue vs Earnings Growth Divergence

Metric	Value	Implication
Revenue growth (YoY)	21.6%	Top-line healthy
Earnings growth (YoY)	8.9%	Temporary: expansion capex absorbing margins
Gross margin	34.6%	Good for EMS (value-add evident)
Operating margin	12.3%	Was 14-15% in FY23-25 — depressed by capex cycle
D/E	~0.5x	Meaningful but manageable; capex peaked FY24

The key question: Revenue growing 22% but profits only 9% because new facilities (OSAT, Manesar, Mysore) carry fixed costs before utilization ramps. Capex fell from ₹1,505 Cr (FY24) → ₹355 Cr (FY25) — the investment phase is behind us. If OPM recovers from 12% → 15-16% as utilization improves, PAT growth re-accelerates to 35-45% while revenue grows 25-30%. This is the crux of the bull case.

Growth Rate Methodology

Why the old model was too conservative: The prior DCF used 30%→12% declining mechanically. This ignored three structural anchors:

1. Industry floor: India EMS market growing at 20-25% CAGR (NITI Aayog; ₹7L Cr by 2026, currently ~₹2.4L Cr). A company with strong design-led capabilities, defence clearances, and PLI benefits should grow at least 5-8% above the market rate. Floor = 25-28%.

2. Capex absorption → margin recovery: KAYNES invested ₹3,000+ Cr in new facilities over FY22-25. As revenue grows into this fixed-cost base, OPM should recover from 12.3% → 15-16% by FY27. That means PAT grows faster than revenue: 28% revenue CAGR × ~1.3x margin recovery lever = ~36% PAT CAGR in the near term.

3. OSAT optionality: The semiconductor packaging (OSAT) facility is a new revenue line not in the base revenue trend. Even modest ramp (₹200-300 Cr by FY27) adds ~8-10% incremental PAT when utilization covers fixed costs.

4. Order book visibility: Strong order book (defence, industrial, automotive) provides multi-year revenue visibility. Revenue shortfall risk in next 2 years is low.

Why CMP is still expensive despite correcting 52%: The issue with KAYNES is not a broken thesis — it is genuine valuation excess. Even with anchored growth rates, the fair value range is ₹1,100-2,400. At ₹3,726, the stock is priced for near-flawless execution over 5+ years. The 52% correction has reduced risk but not eliminated overvaluation.

Model 1: DCF (Capacity-Anchored, Updated Mar 2026)

Base PAT: ₹390 Cr (TTM) | FCF adjustment: 70% Y1-2 (capex winding), 85% Y3+ | Discount rate: 12%

Shares: 6.7 Cr | Debt: ₹903 Cr

Scenario	PAT Growth Rates	Rationale	Terminal	FCF %	Fair Value	vs ₹3,726
Bear	Y1-2: 18%, Y3: 22%, Y4: 20%, Y5: 15%	OPM recovers slowly to 13-14%; revenue grows at EMS market floor of 20-22%; OSAT delays 2 years	5%	70%→85%	₹1,132	-70%
Base	Y1: 25%, Y2: 30%, Y3: 35%, Y4: 28%, Y5: 22%	OPM recovers to 15-16% by FY27 (post-capex leverage); PLI benefits fully realized; OSAT ramps Y3	5%	70%→85%	₹1,669	-55%
Bull	Y1: 30%, Y2: 38%, Y3: 45%, Y4: 38%, Y5: 30%	OPM expands to 18%+ (design-led mix); OSAT profitable from Y3; export order wins	5.5%	65%→85%	₹2,426	-35%

Old vs New DCF comparison:

Scenario	Old Fair Value	New Fair Value	Change	Why it changed
Bear	₹868	₹1,132	+30%	Bear growth anchored to EMS market floor 20%, not mechanically collapsed to 6%
Base	₹1,299	₹1,669	+28%	Base growth anchored to OPM recovery + PLI leverage, not arbitrary 30%→12%
Bull	₹1,848	₹2,426	+31%	Bull includes OSAT ramp as incremental; still terminal 5.5% not 7% (no multi-decade tailwind like T&D)

Model 2: P/B-ROE (Justified Price-to-Book)

Book Value: ₹715 | Cost of Equity: 12% | g = 6%

Scenario	Sustainable ROE	Justified P/B	Fair Value	vs ₹3,726
Bear	10% (compressed OPM persists)	0.67x	₹479	-87%
Base	15% (OPM recovery → 15%)	2.50x	₹1,788	-52%
Bull	22% (OPM 17-18% + asset turnover improves)	8.00x	₹5,720	+54%

P/B-ROE interpretation: Current ROE 11% on rapidly expanding asset base is misleading — it is the trough of the capex cycle. FY23 ROE was ~25%. If OPM recovers and asset turns improve as new capacity fills up, 20-22% ROE is achievable by FY27. Bull case ₹5,720 is technically valid but requires execution certainty we do not yet have.

Why we should weight DCF more heavily here: During heavy capex phases, P/B-ROE overstates value (ROE is artificially compressed by new assets not yet earning). DCF is more conservative and more appropriate for KAYNES right now.

Synthesis: Verdict on KAYNES at ₹3,726

Verdict: Hold only. Do not add. This is not a valuation framework failure — KAYNES is genuinely expensive.

DCF base: ₹1,669 → current price implies a 123% premium over fair value even with generous growth assumptions
Even the bull case DCF (₹2,426) is 35% below CMP
The stock is 52% below peak but remains expensive in absolute terms
The right price to consider adding: <₹2,200 (between base and bull DCF)
The promoter selling overhang (4.3% in 9 months from 57.9% → 53.5%) must resolve before increasing conviction

The one thing that changes this verdict: If Q4 FY26 concall shows OPM recovering to 14%+ and management confirms no further promoter selling, forward PAT trajectory re-rates. At 14% OPM, FY27 PAT could reach ₹650 Cr — at 30x forward P/E = ₹2,910/share. Still below CMP ₹3,726, but the gap closes.

Market cap ₹74,890 Cr. At 35x P/E, needs ₹2,140 Cr profit. At 16% OPM on ₹13,400 Cr revenue. That's 35% revenue CAGR for 5 years plus OPM recovery. Requires perfect execution on OSAT, PLI, defence, and international orders simultaneously. Ambitious — priced in at current levels.

6. Risks

Risk	Probability	Impact	Mitigation
OSAT execution risk — capex heavy, unproven territory	High	High	Management has EMS track record, but semicon is different
Margin pressure from competition + raw material costs	Medium	Medium	Moving up value chain to design-led manufacturing
Debt increasing with expansion (D/E ~0.5)	Medium	Medium	Order book provides revenue visibility
Customer concentration risk	Medium	Medium	Diversifying across automotive, defence, industrial
P/E compression if growth slows	High	High	At 64x P/E, even small miss causes sharp correction

7. Exit Triggers

[ ] Revenue growth drops below 20% YoY for 2 consecutive quarters
[ ] OPM declines below 12% (margin erosion)
[ ] Promoter holding drops below 45%
[ ] OSAT project faces major delays or cost overruns
[ ] Debt/Equity exceeds 1.0

8. Review Schedule

Next quarterly check: Q4 FY26 results (April/May 2026)
Key events to watch:
OSAT facility progress and timeline
New order wins (defence, automotive)
Quarterly margin trends
Capacity utilization at new plants

9. Decision History

Date	Action	Price	Quantity	Reasoning
Multiple	BUY	₹3,923 avg	31	India EMS growth story, defence localization, OSAT optionality

10. Position Sizing Note

12% of portfolio — reasonable for Grade B conviction. However, valuation is stretched at 64x P/E. Both DCF and P/B-ROE models suggest the stock is priced for near-perfect execution. Consider:

Hold if conviction in OSAT + margin expansion is high
Don't add at current levels — wait for correction or earnings to catch up
This is a "hold and monitor" position, not an "add aggressively" one

11. Research Log

New learnings, commentary, and thesis updates — most recent first.

Full edit history: git log research/KAYNES.md

2026-03-12 — v2: Screener.in data + FCF analysis + promoter holding update

Key Screener.in findings (significantly update v1 thesis):

Annual P&L (FY21→FY25):

Year	Revenue (Cr)	Op Profit (Cr)	OPM%	Net Profit (Cr)	EPS
FY21	420	42	10%	10	₹13.79
FY22	706	95	13%	42	₹9.03
FY23	1,126	170	15%	95	₹16.37
FY24	1,805	257	14%	183	₹28.68
FY25	2,722	416	15%	293	₹45.84

Revenue CAGR FY21-FY25: 59% | Profit CAGR: 130%

Recent Quarterly Trend:

Quarter	Revenue (Cr)	Net Profit (Cr)	OPM%
Sep 2024	572	60	14%
Dec 2024	661	66	14%
Mar 2025	984	116	17%
Jun 2025	673	75	17%
Sep 2025	906	121	16%
Dec 2025	804	77	15%

OPM recovering to 15-17% — margins improving, not collapsing.

Cash Flow (critical concern):

Year	CFO (Cr)	Capex (Cr)	FCF (Cr)
FY23	-42	494	-536
FY24	70	1,505	-1,435
FY25	-82	355	-437

FCF is deeply negative — KAYNES is in heavy investment phase. Capex peaked in FY24 (₹1,505 Cr) and dropped sharply to ₹355 Cr in FY25. As capex normalizes, FCF should turn positive from FY26-27.

Shareholding (investigated 2026-03-25 — concern downgraded from "serious" to "moderate"):

Quarter	Promoter %	QoQ Change	FII %	DII %
Mar 2023	63.57%	—	—	—
Dec 2023	57.83%	-5.74%	—	—
Mar 2025	57.75%	0.00%	11.17%	16.98%
Jun 2025	53.52%	-4.23%	12.55%	20.73%
Sep 2025	53.46%	-0.06%	10.96%	23.66%
Dec 2025	53.46%	0.00%	8.87%	16.73%

Key finding: Total 10.1% decline since Mar 2023 happened in exactly two discrete block sales (Dec 2023: -5.74%, Jun 2025: -4.23%), not continuous drip-selling. Selling has stopped for 2 consecutive quarters (Sep-Dec 2025 change is only -0.06%, likely ESOP dilution). No promoter pledge detected. Promoters still hold 53.46% — above the 50% comfort threshold and well above our 40% kill filter. FII exit (-6% from peak) is broader market trend, not KAYNES-specific. The lack of management explanation for the block sales remains the core issue — Q4 FY26 concall is the resolution point.

D/E correction: Screener shows D/E = 0.33 (not 18.9 as yfinance showed — yfinance was wrong, likely including client advances).

Revised thesis:

Business fundamentals are healthy (OPM 15-17%, not compressing)
The stock fell 52% because capex peaked and FCF was deeply negative — market didn't like cash burn
Capex is now normalizing. FY26 FCF should improve significantly
BUT promoter selling of 4.3% is a serious concern — requires explanation
D/E 0.33 is actually fine — the leverage concern was a data error

Verdict update: Thesis partially intact. Hold. The capex-driven FCF trough may be the entry opportunity. The promoter selling is the key risk to resolve via Groww concall transcript or NSE filings.

At current pace, KAYNES is a "watch and wait" — monitor Q4 FY26 results and promoter filing

2026-03-11 — Initial thesis created

Built 2-model valuation: DCF (very bearish at current price), P/B-ROE (bearish unless ROE improves to 20%+)
Key insight: Market implies 53% FCF CAGR or 31% ROE — both aggressive vs actuals (49% sales CAGR, 11% ROE)
The ROE gap (11% actual vs 31% implied) is concerning. KAYNES needs margin expansion + asset efficiency gains.
OSAT entry is the key catalyst — if it works, transforms the business. If it doesn't, current valuation is hard to justify.
Quality Score: 17/25 (Grade B). MOAT 3, Management 4, Financials 3, Growth 5, Valuation 2.